OFIX
Orthofix Medical Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
10.24
▲ 0.23 (2.32%)
MARKET · —
Price
Open
10.14
Prev close
10.01
Day high
10.07
Day low
9.78
Volume
401.36K
Market cap
$404.62M
P/E (TTM)
—
52W range
8.85 – 16.99
Trailing performance
Returnvs SPY
1W
-3.19%
-1.8%
1M
-8.67%
-12.4%
3M
-3.84%
-6.9%
6M
-27.83%
-38.9%
YTD
-33.97%
-46.3%
1Y
-31.11%
-51.1%
3Y
-45.36%
-119.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$404.62M
Enterprise value$565.82M
Revenue (TTM)$833.19M
Gross profit$593.73M
EBITDA$20.93M
Net income$-61.72M
EPS (TTM)$-1.52
Free cash flow$4.10M
Total cash$103.81M
Total debt$261.90M
Book value / share$10.54
Shares outstanding40.42M
Float40.41M
Short % of float5.89%
Dividend yield—
Beta (5Y)0.67
Valuation & profitability ratios
Trailing P/E—
Forward P/E27.05
PEG ratio48.83
Price / sales—
Price / book0.95
EV / revenue0.68
EV / EBITDA27.04
Gross margin71.26%
Operating margin-3.26%
Profit margin-7.41%
Return on equity-13.91%
Return on assets-2.74%
Debt / equity61.02
Current ratio2.84
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $822.31M | $799.49M | $746.64M | $460.71M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$92.19M | -$126.00M | -$151.40M | -$19.75M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$92.19M | -$126.00M | -$151.40M | -$19.75M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.03 | 0.07 | +334.0% |
| Mar 2026 | -0.29 | -0.11 | +61.0% |
| Dec 2025 | 0.42 | 0.24 | -42.7% |
| Sep 2025 | 0.12 | 0.20 | +64.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.11 | 1 | $210.69M | +2.5% |
| Next quarter | 0.35 | 1 | $232.75M | +5.8% |
| Current year | 0.41 | 1 | $850.96M | +3.5% |
| Next year | 0.37 | 1 | $871.91M | +2.5% |
Analyst targets & ownership
Mean target$13.00
High target$14.00
Low target$12.00
Implied upside26.92%
Analyst count4
ConsensusBUY
Strong buy / Buy1 / 2
Hold2
Sell / Strong sell0 / 0
Held by insiders2.17%
Held by institutions95.26%
Institutions holding200
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+428.14K
Net buying
Buy transactions
19
710.15K shares
Sell transactions
11
282.00K shares
Net transactions
+30
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
885.53K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 18, 26 | MCPHERRON AVIVA Officer |
SELL | 3.67K | $34.42K | Direct |
| Jun 10, 26 | HENNEMAN JOHN BELL III Director |
STOCK | 14.96K | $0 | Direct |
| Jun 10, 26 | CAPPS VICKIE LYNN Director |
STOCK | 14.96K | $0 | Direct |
| Jun 10, 26 | MANIAR SHWETA SINGH Director |
STOCK | 14.96K | $0 | Direct |
| Jun 10, 26 | BURRIS WAYNE C. Director |
STOCK | 14.96K | $0 | Direct |
| Jun 10, 26 | BAZAAR ALAN LEE Director |
STOCK | 14.96K | $0 | Direct |
| Jun 10, 26 | HANNON JASON M Director |
STOCK | 14.96K | $0 | Direct |
| Jun 10, 26 | FINEGAN MICHAEL M Director |
STOCK | 20.72K | $0 | Direct |
| Jun 10, 26 | KUMMETH CHARLES R Director |
STOCK | 14.96K | $0 | Direct |
| Jun 10, 26 | PAOLUCCI MICHAEL E Director |
STOCK | 14.96K | $0 | Direct |
| May 22, 26 | JUNIPER INVESTMENT COMPANY, LLC Beneficial Owner of more than 10% of a Class of Security |
SELL | 242.00K | $2.59M | Indirect |
| May 7, 26 | HENNEMAN JOHN BELL III Director |
BUY | 5.00K | $61.30K | Direct |
| May 7, 26 | ENGINE CAPITAL MANAGEMENT, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 184.90K | $2.23M | Indirect |
| Apr 16, 26 | CEDRON JORGE ANDRES Officer |
SELL | 3.74K | $47.98K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDREWS JULIE |
Chief Financial Officer | 88.75K | Sale |
CALAFIORE MASSIMO |
Chief Executive Officer | 320.14K | Sale |
ENGINE CAPITAL MANAGEMENT, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
FINEGAN MICHAEL M |
Director | 81.62K | Stock Award(Grant) |
HANNON JASON M |
Director | 87.66K | Stock Award(Grant) |
HENNEMAN JOHN BELL III |
Director | 105.77K | Stock Award(Grant) |
JUNIPER INVESTMENT COMPANY, LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
KUMMETH CHARLES R |
Director | 76.31K | Stock Award(Grant) |
PAOLUCCI MICHAEL E |
Director | 102.73K | Stock Award(Grant) |
VITALE LUCAS S |
Chief Operating Officer | 160.45K | Sale |
Moving averages & technicals
SMA 10
10.23
+0.17% from price
SMA 20
10.90
-8.14% from price
SMA 50
10.60
-5.61% from price
SMA 100
11.04
-7.24% from price
SMA 200
12.56
-20.32% from price
EMA 12
10.39
-1.41% from price
EMA 26
10.66
-3.92% from price
EMA 50
10.79
-5.09% from price
RSI (14)
41.0
Neutral
MACD (12,26,9)
-0.27
Hist -0.11
ATR (14)
0.56
5.60% of price
Realised vol 30D
65.1%
Annualised
Bollinger upper
12.64
20, 2σ
Bollinger lower
9.16
20, 2σ
50 / 200 cross
Death
10.60 vs 12.56
Trend bias
Below 200
-20.32%
Risk profile
Beta vs SPY
0.70
Less volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
65.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-44.9%
Peak to trough
Max drawdown 5Y
-79.1%
Peak to trough
ATR 14
0.56
5.60% of price
Beta (reported)
0.67
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.22
Positioning, not flow
Max pain
10.00
-0.1% from spot
ATM implied vol
51.6%
Nearest strike to spot
Skew (10% OTM)
+39.6%
Puts bid over calls
Call volume
7
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
10.00
3 contracts
Heaviest put OI
10.00
2 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Orthofix Medical Sees Reimbursement Rebound, but Spine Slump Clouds Outlook
MarketBeat · 7d ago
Orthofix (OFIX) Q2 2026 Earnings Call Transcript
Motley Fool · 10d ago
Barrington Research Adjusts Orthofix Medical PT to $14 From $17, Maintains Outperform Rating
MT Newswires · 16d ago
Orthofix Medical Inc (OFIX) (Q2 2026) Earnings Call Highlights: Strategic Moves and Raised ...
GuruFocus.com · 17d ago
Orthofix Medical Q2 Earnings Call Highlights
MarketBeat · 17d ago
Orthofix Medical Inc. Q2 2026 Earnings Call Summary
Moby · 17d ago
Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates
Zacks · 17d ago
Orthofix: Q2 Earnings Snapshot
Associated Press · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.